Venrock Healthcare Capital Partners III L.P. 13D and 13G filings for 4D Molecular Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 8:51 pm Purchase | 2023-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT | Venrock Healthcare Capital Partners III L.P. | 4,400,000 8.900% | 1,512,483 (+52.38%) | Filing |
| 2023-05-15 4:17 pm Purchase | 2023-05-05 | 13G | 4D Molecular Therapeutics, Inc. FDMT | Venrock Healthcare Capital Partners III L.P. | 2,887,517 8.700% | 2,887,517 (New Position) | Filing |